Stocktoria
Silence Therapeutics plc SLN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-01-05
Silence Therapeutics plc statistics & valuation
Market cap$472.3M
P / B7.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Gross margin | 61.5% | 72.7% | 59.3% |
| Operating margin | -16292.8% | -146.4% | -203.5% |
| Net margin | -15851.9% | -104.7% | -171.4% |
| FCF margin | -11149.6% | -156.9% | -156.5% |
| Return on assets | -67.4% | -22.4% | -45.4% |
| Return on equity | -142.2% | -33.8% | -246.6% |
| Current ratio | 8.72 | 11.14 | 4.62 |
| Revenue growth | -98.7% | 36.7% | — |
Source: SEC EDGAR filings · CIK 0001479615 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.